Table 4: Details in patients pre-treated with pertuzumab.
| Number of patients (%) | ||
| Total | 41 | |
| Number of previous regimens for metastatic breast cancer | ||
| 0 | 0 | |
| 1 | 11 (27%) | |
| 2 | 5 (12%) | |
| 3 | 6 (15%) | |
| ≥ 4 | 19 (46%) | |
| Response to T-DM1 | ||
| Complete response | 2 (5%) | |
| Partial response | 10 (24%) | |
| Long stable disease (≥ 6 months) | 7 (17%) | |
| Stable disease (< 6 months) | 6 (15%) | |
| Progressive disease | 14 (34%) | |
| Not evaluable | 2 (5%) | |
| Response rate | 29% | |
| Clinical benefit rate | 46% | |
| Median time to treatment failure, months (range) | 5.0 (0.7-21.0) | |
| Adverse events (Grade 3/4) | ||
| Thrombocytopenia | 9 (22%) | |
| Increased ALT and/or AST | 3 (7%) | |
| Rash | 0 | |
| Neutropenia | 1 (2%) | |